684 patents
Page 3 of 35
Utility
Flow Restrictor for Drug Delivery Device
2 Nov 23
A drug delivery device includes a housing, a container disposed in the housing, a drive mechanism, a needle assembly, a fluid flow path, and a vortex flow adapter.
Ali Nekouzadeh, Mehran Mojarrad, Joshua Tamsky, Paul Daniel Faucher, Scott R. Gibson, Kimberly Sepulveda, Sheldon B. Moberg
Filed: 17 Nov 20
Utility
Selecting Resins for Use in Chromatography Purification Processes
2 Nov 23
A method of selecting raw materials for use in a column chromatography purification process in which, for each of one or more candidate resins, a respective set of resin attribute values is received, including at least one analytical measurement of the candidate resin.
Hector Nogueras, Myra Coufal, Deborah Soto-Ortega
Filed: 16 Jul 21
Utility
Pharmaceutical Formulation
2 Nov 23
The disclosure provides a formulation comprising, e.g., a bispecific antibody construct, a buffer, a saccharide, a surfactant, and methionine.
Bharadwaj Jagannathan
Filed: 23 Aug 21
Utility
Methods of Measuring Carfilzomib
2 Nov 23
Provided herein are improved methods for measuring the concentration of carfilzomib in a sample.
Emma Harper, Dawn Elyse Cohen
Filed: 18 Jun 21
Utility
CXCR6 Sulfonamide Compounds
26 Oct 23
Hiufung CHU, Pingchen FAN, Yandong LI, Viengkham MALATHONG, Jay POWERS, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
Filed: 20 Mar 23
Utility
Long-term Medicament Storage Apparatus and Methods
19 Oct 23
An apparatus for storing a medicament delivery device, the apparatus comprising: a container defining a storage cavity having an opening, the storage cavity configured to receive a syringe pre-filled with medicament; an absorbent disposed in the cavity, the absorbent at least partially hydrated with a liquid solution; and a seal member at least selectively connected with the cavity to form a seal that is at least substantially gas impermeable.
Alan Dominguez, Nicholas J. Clark
Filed: 3 Sep 21
Utility
Materials and Methods to Reduce Protein Aggregation
19 Oct 23
Provided herein are methods of treating a neoplastic disease in a subject.
Arnold J. MCAULEY, Michael SCHNEIDER
Filed: 10 Sep 21
Utility
Chimeric Receptors and Methods of Use Thereof
19 Oct 23
Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention.
Jed WILTZIUS, Ruben ALVAREZ RODRIGUEZ, Alice BAKKER, Lawren WU, Tara ARVEDSON
Filed: 3 Mar 23
Utility
Immunogens Derived from SARS-COV2 Spike Protein
12 Oct 23
The present invention relates to severe acute respiratory syndrome coronavirus 2 (“SARS-CoV2”) immunogens useful for the generation of therapeutic antibodies and vaccine development.
Fernando GARCES, Zhulun WANG, Timothy RILEY
Filed: 22 Jul 21
Utility
Heteroaryl-biphenyl Amides for the Treatment of PD-L1 Diseases
12 Oct 23
Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
Filed: 12 Jun 23
Utility
Antigen Binding Proteins with Non-canonical Disulfide In Fab Region
12 Oct 23
The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic.
Fernando GARCES, Zhulun WANG
Filed: 19 Aug 21
Utility
Overexpression of Insulin-like Growth Factor Receptor Mutants to Modulate Igf Supplementation
12 Oct 23
Methods of mammalian cell culture for expressing a recombinant protein of interest are provided.
Kristine Marie DARIS, Fides Dwinan LAY
Filed: 1 Nov 21
Utility
MCL-1 Inhibitor Formulations
5 Oct 23
Provided herein are solid dispersions comprising AMG 397, methods of preparing the solid dispersion, and pharmaceutical formulations comprising AMG 397.
JAMES E. HUCKLE, MARKIAN M. STEC, TIAN WU, DARREN L. REID, FERNANDO A. ALVAREZ-NUNEZ, SEAN P. BROWN
Filed: 24 Aug 21
Utility
Method of Making Lyophilized Protein Formulations
5 Oct 23
Disclosed herein are methods of preparing lyophilized formulations comprising a protein, such as an antibody or a bispecific antibody construct, that exhibits improved storage stability.
Arnold McAuley, Michael J. Treuheit, Twinkle R. Christian, Bharadwaj Jagannathan
Filed: 14 Sep 21
Utility
Monoclonal Antibodies to Chemically-modified Nucleic Acids and Uses Thereof
5 Oct 23
The present invention relates to monoclonal antibodies that specifically bind to chemically-modified nucleic acid molecules, including pan-specific antibodies that bind to chemically-modified nucleic acid molecules independent of nucleotide sequence.
Brian CHAN, Weihsu Claire CHEN, Sara HUMPHREYS, Agnieszka KIELCZEWSKA, Mai THAYER
Filed: 22 Mar 21
Utility
Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
5 Oct 23
Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.
Francisco Leon, Wayne H. Tsuji
Filed: 24 Mar 23
Utility
Salt Forms and Solvates of MCI-1 Antagonists
5 Oct 23
Henry Morrison, Jason S. Tedrow, Stephan D. Parent, Courtney Johnson, Travis Houston, Melanie Bevill
Filed: 5 Apr 23
Utility
Antibody Constructs for DLL3 and CD3
5 Oct 23
The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell.
Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
Filed: 21 Dec 22
Utility
Processes of Making and Crystalline Forms of a MDM2 Inhibitor
28 Sep 23
The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates.
Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNATSOS, Sean H. WIEDEMANN, Sarah WORTMAN
Filed: 8 May 23
Utility
Swallowable Drug Delivery Devices
28 Sep 23
A swallowable drug delivery device includes a capsule and a tissue attachment member.
Mehran Mojarrad, Scott R. Gibson, Scott Castanon, Robert Eisele, Dylann Ceriani
Filed: 2 Sep 21